BD Oncomark™ Anti-Human CD103 FITC/CD22 PE/CD20 PerCP-Cy™5.5 341122

Reactivity: Human
Application: Flow cytometry
Regulatory Status: RUO (GMP)
RRID: AB_647453
Storage Buffer: Phosphate buffered saline with BSA and 0.1% sodium azide.
Description: Description CD103, clone Ber-ACT 8, is derived from hybridization of spleen cells from BALB/c mice immunized with HTLV-1 positive cell line (MAPS16). CD22, clone S-HCL-1, is derived from hybridization of mouse NS-1 myeloma cells with spleen cells from CD-1 mice immunized with whole cells and membrane preparations of hairy-cell leukemia cells. CD20, clone L27, is derived from hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with the LB lymphoblastoid cell line. CD103 recognizes the α E subunit of integrin α E β 7 , an integrin also known as the human mucosa lymphocyte (HML) antigen but not α 4 , another member of the β 7 integrin subfamily. Integrin   α E β 7 is a trimeric protein complex of three components, 105 kilodaltons (kd) (β 7 ), 150 kd, and 25 kd. The CD103 epitope is localized on the 150-kd chain. CD22 recognizes a human B-lymphocyte antigen, Mr 135 kd. The CD20 antigen is a phosphoprotein with a molecular weight of 35 or 37 kd depending on the degree of phosphorylation. The antigen is not glycosylated.
Preparation And Storage: Preparation And Storage Store vials at 2–8°C. Do not freeze reagents; protect them from prolonged exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.
Description : Clone : Isotype : EntrezGene ID
N/A : N/A : IgG2b, κ,IgG2a, κ,IgG1, κ : N/A